Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances

View original at finance.yahoo.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances GALWAY, Ireland, Feb…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • These milestones reflect unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition

    80% confidence
  • By broadening sensor and insulin options for the MiniMed 780G system, more people will benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management

    80% confidence
  • MiniMed 780G system automatically adjusts insulin delivery every five minutes, responding to glucose changes, supporting more stable glucose control with fewer highs and lows and less daily decision-making

    80% confidence
  • Anyone who requires insulin therapy to manage their diabetes, whether type 1 or type 2, can benefit from automated insulin delivery

    80% confidence
  • More people living with type 2 diabetes will get access to life-changing technology improving their day-to-day experience in managing their diabetes

    80% confidence
  • Instinct sensor offers up to 15 days of wear and is the world's smallest and thinnest integrated CGM

    80% confidence
  • Ultra rapid-acting insulin's faster onset may help reduce the impact of late or missed meal doses, allowing the insulin to catch up more effectively

    80% confidence
  • Bringing together the Instinct sensor with the well-established algorithm of the MiniMed 780G system makes for an extremely effective combination

    80% confidence
  • Medtronic technologies and therapies treat 70 health conditions and transform the lives of two people every second, every hour, every day

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances — Source | Via News | ViaNews Market